<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289035</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125101126</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CZ-CELGENEUS-217-C5013-13013220</safetyreportid>
    <primarysourcecountry>CZ</primarysourcecountry>
    <occurcountry>CZ</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130118</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CZ-CELGENE-217-C5013-13013220</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>CZ-CELGENE-217-C5013-12100435</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportergivename>David</reportergivename>
      <reporterfamilyname>Belada</reporterfamilyname>
      <reportercountry>CZ</reportercountry>
      <qualification>1</qualification>
      <studyname lang="en">2008-003389-25#Phase 2 randomised study of lenalidomide vs. investigator's choice in MCL patients</studyname>
      <sponsorstudynumb>CC-5013-MCL-002</sponsorstudynumb>
      <observestudytype>1</observestudytype>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>J-V</patientinitial>
      <patientinvestigationnumb>1221010</patientinvestigationnumb>
      <patientonsetage>82</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>60</patientweight>
      <patientheight>160</patientheight>
      <patientsex>1</patientsex>
      <resultstestsprocedures lang="en">21Nov2012
-Gastroscopy: infiltration and stenosis of esophagus with bleeding and retention of salines</resultstestsprocedures>
      <patientdeath>
        <patientdeathdateformat>102</patientdeathdateformat>
        <patientdeathdate>20121129</patientdeathdate>
        <patientautopsyyesno>2</patientautopsyyesno>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">OESOPHAGEAL BLEEDING</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10071846</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10030172</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20121124</reactionstartdate>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121121</testdate>
        <testname lang="en">GASTROSCOPY</testname>
      </test>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CC-5013</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10061275</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10071846</drugreactionasses>
          <drugassessmentsource lang="en">1</drugassessmentsource>
          <drugassessmentmethod lang="en">EVCTM</drugassessmentmethod>
          <drugresult lang="en">1</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10071846</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALLOPURINOL</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">100 Milligram</drugdosagetext>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10020907</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2011</drugstartdate>
        <activesubstance>
          <activesubstancename>ALLOPURINOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OXYPHYLLIN</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">200 Milligram</drugdosagetext>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <activesubstance>
          <activesubstancename>ETOFYLLINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIN</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugstructuredosagenumb>2.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">2.5 Milligram</drugdosagetext>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10020775</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESILATE</activesubstancename>
        </activesubstance>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">INVESTIGATOR SAE VERBATIM: OESOPHAGEAL BLEEDING

CC-5013-MCL-002 (Czech Republic): A phase 2, multicenter, randomised, open-label study to determine the efficacy of lenalidomide versus investigator's choice in patients with relapsed or refractory mantle cell lymphoma.

Initial information was received from the investigator on 18Jan2013 regarding an 82 years old male patient, 122-1010, who received study medication CC-5013 (therapy dates unknown) for the treatment of mantle cell lymphoma.  
There were no data provided on medical history.  Concomitant medication included Omeprazole for oesophageal hernia (starting 2011) Allopurinol for hyperuricemia prophylaxis, Amlodipin for arterial hypertension and Oxyphillin for unknown indication.

On 24Nov2012 the patient presented esophageal bleeding (NCI-CTC grade 4); the investigator considered the event life threatening. Gastroscopy on 21Nov2012 showed infiltration and stenosis of esophagus with bleeding and retention of salines.
The patient received Omeprazole iv as treatment for esophageal bleeding, morphine for prophylaxis of respiratory distress and Torecan as antiemetic.
The patient died on 29Nov2012 due to unknown cause; the event esophageal bleeding was ongoing at death. No autopsy has been performed.

The investigator provided the following causality assessment:
Esophageal bleeding: CC-5013 (not provided)
Further information will be requested.

This case is linked to MCN 217-C5013-12100435 (Staphylococcus sepsis)</narrativeincludeclinical>
        <sendercomment lang="en">This 82 year old patient was diagnosed with life-threatening esophageal bleeding during the treatment with CC-5013 for relapsed or refractory Mantle cell lymphoma (treatment dates and time to onset not provided). The patient was taking concomitant Omeprasole for esophageal hernia. Three days before reported life-threatening bleeding a gastroscopy was done that showed infiltration and stenosis of oesophagus with bleeding. Treatment included proton-pump-inhibitors (Omeprasole), morphin and antiemetics. However, the patient died in five days, cause of death was not provided. Esophageal bleeding was ongoing at death. The investigator did not provide causality assesssment. While temporal relationship between therapy and OESOPHAGEAL BLEEDING suggest that a causal relationship cannot be excluded (possible), the case is missing critical information for a meaningful causality assessment. However, esophageal hernia could led to erosions and ulcers and could be considered as a contributory factor. Further information including CC-5013 therapy dates, full gastrointestinal history and risk factors (alcohol use, dietary), clinical symptoms with timing, stage of underlying disease, concomitant medications, including NSAIDs and thromboprophylaxis, diagnostic data will be requested.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
